Clal Insurance Enterprises Holdings Ltd Acquires 1,968,077 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Share on StockTwits

Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 108.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,782,296 shares of the company’s stock after acquiring an additional 1,968,077 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 1.5% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 20th biggest holding. Clal Insurance Enterprises Holdings Ltd owned 0.37% of Teva Pharmaceutical Industries worth $58,323,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bruderman Asset Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock worth $36,000 after buying an additional 2,262 shares in the last quarter. Rational Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $49,000. Capital Investment Advisory Services LLC bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $56,000. Quadrant Capital Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 420.3% during the 4th quarter. Quadrant Capital Group LLC now owns 5,541 shares of the company’s stock worth $80,000 after buying an additional 4,476 shares in the last quarter. Finally, Whittier Trust Co. lifted its position in shares of Teva Pharmaceutical Industries by 35.4% during the 4th quarter. Whittier Trust Co. now owns 5,481 shares of the company’s stock worth $84,000 after buying an additional 1,434 shares in the last quarter. 66.42% of the stock is currently owned by institutional investors and hedge funds.

In related news, VP Notaristefani Carlo De sold 5,041 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total value of $90,133.08. Following the completion of the transaction, the vice president now directly owns 17,162 shares in the company, valued at approximately $306,856.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Richard Daniell sold 2,098 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the transaction, the vice president now owns 2,098 shares of the company’s stock, valued at $35,414.24. The disclosure for this sale can be found here. Insiders sold a total of 16,173 shares of company stock valued at $273,316 over the last quarter. 0.43% of the stock is owned by company insiders.

Several research firms have commented on TEVA. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, December 3rd. Bank of America reissued a “buy” rating and set a $24.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 5th. HSBC set a $12.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research report on Tuesday, February 5th. Credit Suisse Group restated a “hold” rating and set a $26.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, February 5th. Finally, Piper Jaffray Companies upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus target price of $21.21.

Shares of TEVA stock opened at $16.47 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 1.69. Teva Pharmaceutical Industries Ltd has a 12-month low of $14.59 and a 12-month high of $25.96. The company has a market cap of $16.75 billion, a PE ratio of 5.88, a P/E/G ratio of 2.96 and a beta of 1.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The company had revenue of $4.56 billion during the quarter, compared to analyst estimates of $4.52 billion. During the same quarter last year, the business posted $0.93 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 15.5% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.33 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4223017/clal-insurance-enterprises-holdings-ltd-acquires-1968077-shares-of-teva-pharmaceutical-industries-ltd-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Trading Ex-Dividend Strategy

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EBCoin Price Reaches $0.0003 on Top Exchanges
EBCoin Price Reaches $0.0003 on Top Exchanges
Iovance Biotherapeutics Inc  Receives $26.25 Consensus PT from Brokerages
Iovance Biotherapeutics Inc Receives $26.25 Consensus PT from Brokerages
Zacks: Analysts Expect Aduro BioTech Inc  to Announce -$0.17 EPS
Zacks: Analysts Expect Aduro BioTech Inc to Announce -$0.17 EPS
KWHCoin  Trading Up 22.4% Over Last Week
KWHCoin Trading Up 22.4% Over Last Week
WABnetwork Achieves Market Cap of $397,299.00
WABnetwork Achieves Market Cap of $397,299.00
Weekly Investment Analysts’ Ratings Changes for Shopify
Weekly Investment Analysts’ Ratings Changes for Shopify


© 2006-2019 Ticker Report